Switchkine develops pH-activatable cytokines to treat cancer and autoimmune and inflammatory diseases. Selected for the Biopôle Investment Programme's Pre-Clinical Top-Up (CHF 250,000), it will fund proof-of-concept studies.
- Announced on
- Round
- Grant
- Amount
- CHF 250,000
- Location
- Epalinges, canton of Vaud
- Sector
- Biotech & life sciences
Investors
- Biopôle SA lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic